Over 1 Year Ago
1 Min Read
CLNN up 8%. A closer look at the stock:
Shares of Clene Inc (CLNN) are trading 8% higher at a price of $3.92 at the time of this writing. So far the Health Care sector has been having a slightly somber day, and the share price of the company is rapidly outshining it's peers.
- Positive topline results from the Phase 2 VISIONARY-MS trial of CNM-Au
- Potential treatment for MS
- Small trial- data is not yet conclusive enough for investment decision
- Clene still expects CNM-Au8 to show significant neurological improvements over current treatments for MS
- Anticipates reporting full results from the Phase 2 trial late 2022
The price is likely moving on the heels of the recent earnings call on August 08.
Clene Inc has been trading between a 52-week high of $8.6 and a 52-week low of $1.93. The stock has a market cap of $249 Million.
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.
Headlines
Clene (CLNN) Investor Presentation - Slideshow (NASDAQ:CLNN)
Seeking Alpha 08-17-22
Clene Shares Fall Despite Multiple Sclerosis Candidate Showing Neurological Improvements
Benzinga 08-15-22
CLNN stock falls after Phase 2 data for lead drug in multiple sclerosis (NASDAQ:CLNN)
Seeking Alpha 08-15-22
Clene GAAP EPS of -$0.07, revenue of $0.03M
Seeking Alpha 08-15-22
Why Is Turquoise Hill Resources Down By 18%: Here Are 31 Stocks Moving Premarket
Benzinga 08-15-22
Recommended Articles
